Sign in

CIK 0001609809

  • Non-accelerated filer
  • Smaller reporting company

Seres Therapeutics, Inc.

Sign in to watch
Ticker
MCRB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
274326290
Phone
+1 617-945-9626
Business address
200 SIDNEY STREET, CAMBRIDGE, MA, 02139
Former names
Seres Therapeutics, Inc., Seres Health, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$795
in 4 filings, $795 under 10b5-1 plans

Net −$795. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2024-02-14 Henn Matthew R. Grant or award · Stock Option (Right to Buy) 10b5-1 +187,500 187,500
2024-02-14 Henn Matthew R. Grant or award · Stock Option (Right to Buy) 10b5-1 +287,905 287,905
2024-02-14 Henn Matthew R. Grant or award · Restricted Stock Units 10b5-1 +31,250 31,250
2024-02-14 Young Teresa L. Grant or award · Stock Option (Right to Buy) 10b5-1 +187,500 187,500
2024-02-14 Young Teresa L. Grant or award · Stock Option (Right to Buy) 10b5-1 +287,905 287,905
2024-02-14 Young Teresa L. Grant or award · Restricted Stock Units 10b5-1 +31,250 31,250
2024-02-14 von Moltke Lisa Grant or award · Stock Option (Right to Buy) 10b5-1 +213,750 213,750
2024-02-14 von Moltke Lisa Grant or award · Stock Option (Right to Buy) 10b5-1 +287,905 287,905
2024-02-14 von Moltke Lisa Grant or award · Restricted Stock Units 10b5-1 +35,625 35,625
2024-02-14 Ege David S. Grant or award · Stock Option (Right to Buy) 10b5-1 +187,500 187,500
2024-02-14 Ege David S. Grant or award · Stock Option (Right to Buy) 10b5-1 +287,905 287,905
2024-02-14 Ege David S. Grant or award · Restricted Stock Units 10b5-1 +31,250 31,250
2024-02-14 Arkowitz David Chief Financial Officer Grant or award · Stock Option (Right to Buy) 10b5-1 +213,750 213,750
2024-02-14 Arkowitz David Chief Financial Officer Grant or award · Stock Option (Right to Buy) 10b5-1 +287,905 287,905
2024-02-14 Arkowitz David Chief Financial Officer Grant or award · Restricted Stock Units 10b5-1 +35,625 35,625
2023-10-30 Cloghessy Paula Sale 10b5-1 −2,904 $1.35 $4K 45,684
2023-10-30 Shaff Eric D. CEO and President Sale 10b5-1 −8,552 $1.35 $12K 115,620
2023-10-30 Young Teresa L. Sale 10b5-1 −2,907 $1.35 $4K 8,454
2023-10-30 Arkowitz David Chief Financial Officer Sale 10b5-1 −4,066 $1.35 $5K 175,756
2023-10-30 DesRosier Thomas Chief Legal Officer and EVP Sale 10b5-1 −4,156 $1.35 $6K 113,891

Page 16 of 23 · 458 trades